罗红霉素对16种非典型分枝杆菌的体外活性及pH对其放射性测定最低抑菌浓度的影响。
In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs.
作者信息
Rastogi N, Goh K S, Bryskier A
机构信息
Unité de la Tuberculose et des Mycobactéries, Institut Pasteur, Paris, France.
出版信息
Antimicrob Agents Chemother. 1993 Jul;37(7):1560-2. doi: 10.1128/AAC.37.7.1560.
Abstract
The antimycobacterial spectrum of roxithromycin, a semisynthetic 14-membered ring macrolide, was determined against 28 strains belonging to 16 species of atypical mycobacteria by measuring radiometric MICs by BACTEC methodology at two different pH values, i.e., 6.8 and 7.4. The MICs obtained at pH 7.4 were 1 to 2 dilutions lower or more than those obtained at pH 6.8 for some of the species. Roxithromycin possessed promising MICs against such potential pathogens as the Mycobacterium avium complex, M. scrofulaceum, M. szulgai, M. malmoense, M. xenopi, M. marinum, M. kansasii, and rare pathogens like M. chelonei subsp. chelonei and M. chelonei subsp. abscessus but not against M. simiae. Roxithromycin showed lower MICs against M. fortuitum var. peregrinum than M. fortuitum var. fortuitum.
摘要
通过采用BACTEC方法在两个不同pH值（即6.8和7.4）下测量放射性最低抑菌浓度（MIC），测定了半合成14元环大环内酯类药物罗红霉素对属于16种非典型分枝杆菌的28株菌株的抗分枝杆菌谱。对于某些菌种，在pH 7.4时获得的MIC比在pH 6.8时低1至2倍稀释度或更低。罗红霉素对诸如鸟分枝杆菌复合群、瘰疬分枝杆菌、苏尔加分枝杆菌、马尔默分枝杆菌、偶发分枝杆菌、海分枝杆菌、堪萨斯分枝杆菌等潜在病原体以及像龟分枝杆菌龟亚种和龟分枝杆菌脓肿亚种等罕见病原体具有良好的MIC，但对猿分枝杆菌无效。罗红霉素对偶然分枝杆菌流浪变种的MIC比对偶然分枝杆菌偶然变种的MIC低。
相似文献
1
In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs.
Antimicrob Agents Chemother. 1993 Jul;37(7):1560-2. doi: 10.1128/AAC.37.7.1560.
2
Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria.
Antimicrob Agents Chemother. 1992 Dec;36(12):2841-2. doi: 10.1128/AAC.36.12.2841.
3
Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
Antimicrob Agents Chemother. 1996 Nov;40(11):2483-7. doi: 10.1128/AAC.40.11.2483.
4
In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex.
Antimicrob Agents Chemother. 1995 May;39(5):1162-5. doi: 10.1128/AAC.39.5.1162.
5
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.
Antimicrob Agents Chemother. 1994 Jun;38(6):1433-8. doi: 10.1128/AAC.38.6.1433.
6
Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs?
Zentralbl Bakteriol. 1992 Dec;277(4):474-84. doi: 10.1016/s0934-8840(11)80472-x.
7
Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.
Antimicrob Agents Chemother. 1992 Jan;36(1):180-4. doi: 10.1128/AAC.36.1.180.
8
Activity of ciprofloxacin against Mycobacteria in vitro: comparison of BACTEC and macrobroth dilution methods.
J Antimicrob Chemother. 1987 May;19(5):617-22. doi: 10.1093/jac/19.5.617.
9
In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria.
Antimicrob Agents Chemother. 2003 May;47(5):1736-8. doi: 10.1128/AAC.47.5.1736-1738.2003.
10
Sensitivity of opportunist mycobacteria to rifampicin and ethambutol.
Tubercle. 1981 Jun;62(2):117-21. doi: 10.1016/0041-3879(81)90019-2.
引用本文的文献
1
Disseminated Mycobacterium scrofulaceum Infection in an Immunocompetent Host.
Intern Med. 2017;56(14):1931-1935. doi: 10.2169/internalmedicine.56.8181. Epub 2017 Jul 15.
2
Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
Antimicrob Agents Chemother. 1996 Nov;40(11):2483-7. doi: 10.1128/AAC.40.11.2483.
3
Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.
Antimicrob Agents Chemother. 1996 Apr;40(4):1033-5. doi: 10.1128/AAC.40.4.1033.
4
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.
Antimicrob Agents Chemother. 1994 Jun;38(6):1433-8. doi: 10.1128/AAC.38.6.1433.
5
Intracellular concentrations of antibacterial agents and related clinical implications.
Clin Pharmacokinet. 1994 Jul;27(1):63-84. doi: 10.2165/00003088-199427010-00006.
6
Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages.
Antimicrob Agents Chemother. 1995 Apr;39(4):976-8. doi: 10.1128/AAC.39.4.976.
7
Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice.
Antimicrob Agents Chemother. 1995 Apr;39(4):878-81. doi: 10.1128/AAC.39.4.878.
8
Potential role of roxithromycin against the Mycobacterium avium complex.
Infection. 1995;23 Suppl 1:S28-32. doi: 10.1007/BF02464957.
9
In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex.
Antimicrob Agents Chemother. 1995 May;39(5):1162-5. doi: 10.1128/AAC.39.5.1162.
10
Lesser known mycobacteria.
J Clin Pathol. 1995 Aug;48(8):701-5. doi: 10.1136/jcp.48.8.701.
本文引用的文献
1
Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin.
Antimicrob Agents Chemother. 1985 Mar;27(3):314-9. doi: 10.1128/AAC.27.3.314.
2
In vitro susceptibility of Mycobacterium avium to a new macrolide (RU-28965).
Chemotherapy. 1987;33(4):255-8. doi: 10.1159/000238504.
3
In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.
Antimicrob Agents Chemother. 1989 Sep;33(9):1614-6. doi: 10.1128/AAC.33.9.1614.
4
[In vitro sensitivity of Mycobacterium avium and Mycobacterium xenopi to erythromycin, roxithromycin and doxycycline].
Pathol Biol (Paris). 1989 Jun;37(5 Pt 2):565-7.
5
New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.
Antimicrob Agents Chemother. 1989 Sep;33(9):1419-22. doi: 10.1128/AAC.33.9.1419.
6
New directions for macrolide antibiotics: structural modifications and in vitro activity.
Antimicrob Agents Chemother. 1989 Sep;33(9):1413-8. doi: 10.1128/AAC.33.9.1413.
7
Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic.
Infect Immun. 1991 May;59(5):1823-31. doi: 10.1128/iai.59.5.1823-1831.1991.
8
Intracellular distribution and activity of antibiotics.
Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):100-6. doi: 10.1007/BF01964420.
9
Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.
Antimicrob Agents Chemother. 1991 Mar;35(3):462-70. doi: 10.1128/AAC.35.3.462.
10
Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.
Antimicrob Agents Chemother. 1991 Dec;35(12):2473-80. doi: 10.1128/AAC.35.12.2473.
Zotero 插件